IMMUNEERING CORPORATIO

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

12 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

20 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

12 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Immuneering to Present at the Morgan Stanley Healthcare Conference

06 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

03 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

05 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Immuneering to Present at the Jefferies Healthcare Conference

30 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

04 May 2023 16:05:02 By Nasdaq GlobeNewswire

Immuneering Announces $30 Million Underwritten Offering

18 Apr 2023 09:24:15 By Nasdaq GlobeNewswire

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

18 Apr 2023 09:00:02 By Nasdaq GlobeNewswire

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

12 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

05 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

28 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

14 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

06 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

05 Mar 2023 18:30:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in March Investor Conferences

28 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

27 Feb 2023 08:00:01 By Nasdaq GlobeNewswire